TOI ONCOLOGY INSTITUTE INC (THE)

The Oncology Institute Announces New Leaders to Oversee Technology and Clinical Trials

The Oncology Institute Announces New Leaders to Oversee Technology and Clinical Trials

Phil Reger and Cristina Green Will Serve as the Chief Information Officer and Vice President of Clinical Research, Respectively

CERRITOS, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, is pleased to announce the hiring of two new executives. Phil Reger will serve as the Chief Information Officer and Cristina Green will serve as the Vice President of Clinical Research.

As Chief Information Officer, a newly created position, Mr. Reger will lead enterprise-wide technology and data initiatives, developing strategies to support TOI’s growth. Mr. Reger’s professional experience includes 25 years of IT experience in high-growth environments, with 20 of them specializing in healthcare. Before joining TOI, Mr. Reger was part of the founding team that launched Radiology Partners, the largest radiology practice in the United States. As CTO, he launched and grew an IT department that met business demands for high levels of acquisitive growth, reliable clinical systems, and advanced capabilities. Most recently, he partnered with visionary clinicians and data scientists to develop an artificial intelligence platform enabling physicians to deliver industry-leading levels of patient care. Prior to Radiology Partners, he served as a key member of the DaVita IT leadership team.

In her new role as Vice President of Clinical Research, Ms. Green will oversee the clinical research arm of TOI and expand access to clinical trials for TOI patients. Ms. Green’s clinical research experience spans over 24 years across several different areas including data management, project management, clinical operations, and functional leadership. Most recently, she held roles at Labcorp Drug Development spearheading transformational initiatives for the conduct of clinical trials, including mobile health, decentralized clinical trials, and other study design innovations via data, technology, and process optimization. Ms. Green also led large multi-country based clinical operations teams during her tenure as Executive Director for Latin America from 2015–2017 and Executive Director for North America from 2011–2015.

TOI’s CEO Brad Hively commented, “TOI thrives on incredible leadership, and I couldn’t be more excited about these two seasoned leaders joining our team. The roles that Phil and Cristina fill are especially vital as we enhance our focus on research, technology, and health equity. I am confident that their contributions will help us advance even further.”

About The Oncology Institute

Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.6 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced healthcare organizations. With 80+ employed clinicians and more than 600 teammates in more than 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit .

Contacts

Media

The Oncology Institute

Julie Korinke



(562) 735-3226 x 88806

Juan Lezama

(562) 374-8434

Investors

Solebury Trout

Maria Lycouris



EN
11/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ONCOLOGY INSTITUTE INC (THE)

 PRESS RELEASE

The Oncology Institute Reports Fourth Quarter and Full Year 2025 Finan...

The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026 CERRITOS, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2025. Recent Operational Highlights Cash flow from operations in Q4 2025 was approximately $3.2 million, due to disciplined working capital management and overall increase in gross profit marginConti...

 PRESS RELEASE

The Oncology Institute Announces Fourth Quarter and Full Year 2025 Ear...

The Oncology Institute Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call CERRITOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI)  a pioneer in value-based community oncology care, today announced that the company will release its fourth quarter and full year 2025 financial results on Thursday, March 12, 2026, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-...

 PRESS RELEASE

The Oncology Institute to Participate in Multiple Healthcare Investor ...

The Oncology Institute to Participate in Multiple Healthcare Investor Conferences in March CERRITOS, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), a pioneer in value-based community oncology care, today announced that members of its executive leadership team will participate in several investor conferences in March. Details for the conferences are as follows: Jefferies Healthcare Services Innovation & Technology SummitPresentation: Monday, March 9, 2026, from 11:30 a.m. to 12:00 p.m. ETLocation: Miami, FLPresenter: Dr. Daniel Virnich, Chief Execut...

 PRESS RELEASE

The Oncology Institute Appoints Kim Tzoumakas to Board of Directors

The Oncology Institute Appoints Kim Tzoumakas to Board of Directors CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously held the CEO r...

 PRESS RELEASE

The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminar...

The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminary 2026 Outlook CERRITOS, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based oncology groups in the United States, today reaffirmed 2025 guidance and provided its preliminary 2026 outlook. 2026 Outlook For 2026, TOI anticipates that total revenue will be in the range of $630 million to $650 million, reflecting 28% growth from the midpoint of 2025 and 2026 guidance ranges, and including approximately $150 million of Capitation rev...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch